研究单位：[1]The Children's Hospital of Zhejiang University School of Medicine[2]Tongji Hospital Wuhan, Hubei, China, 430030[3]Second Xiangya Hospital of Central South University Changsha, Hunan, China, 410011[4]Nanjing Children's Hospital Nanjing, Jiangsu, China, 210008[5]Children's Hospital of Soochow University Suzhou, Jiangsu, China, 215002[6]Shandong Provincial Hospital Jinan, Shandong, China, 250021[7]Children's Hospital of Fudan University Shanghai, Shanghai, China, 201102[8]Chengdu Women and Children's Center Hospital Chengdu, Shichuan, China, 610043[9]The Children Hospital of Zhejiang University School of Medicine Hangzhou, Zhejiang, China, 310006[10]Peking University First Hospital Beijing, Beijing, China, 100032[11]Children's Hospital of Chongqing Medical University Chongqing, Chongqing, China, 401122[12]First Affiliated Hospital of Zhongshan Medical University Guangzhou, Guangdong, China, 510080[13]Henan Children's Hospital Zhengzhou, Henan, China, 451161
Primary nephrotic syndrome accounts for approximately 90% of the total number of nephrotic syndrome in childhood and it is the most common glomerular disease in children. Although treatment with steroids is uesful for primary nephrotic syndrome, proning to cause frequent relapse/steroid-dependent nephrotic syndrome after treatment, and the usage of immunosuppressive agents has become a new choice for the treatment of such patients. This study is a prospective, randomized, multicenter, open, parallel controlled trial, evaluating the efficacy and safety of steroid combined with the immunosuppressive agents which are tacrolimus and mycophenolate mofetil to children who with frequently relapsing or steroid-dependent nephrotic syndrome, all we wish to obtain the proper drug choice and individualized treatment options for children with nephrotic syndrome.
